Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Osteoporos Int. 2009 Nov;20(11):1969-72. doi: 10.1007/s00198-009-0840-2. Epub 2009 Jan 29.
Pathologic fractures are often excluded in epidemiologic studies of osteoporosis. Using Medicare administrative data, we identified persons with vertebral and hip fractures. Among these, 48% (vertebral) and 3% (hip) of the fractures were coded as pathologic. Only 25% and 66% of persons with these pathologic fractures had evidence for malignancy.
Analyses of osteoporosis-related fractures that use administrative data often exclude pathologic fractures (ICD-9 733.1x) due to concern that these are caused by cancer. We examined "pathologic" fractures of the vertebrae and hip to evaluate their contribution to fracture incidence and assessed the evidence for a malignancy.
We studied US Medicare beneficiaries age > or =65 with new fractures identified using ICD-9 diagnosis codes 733.13 (pathologic vert), 805.0, 805.2, 805.4, 805.8 (nonpathologic vert); and 733.14 (pathologic hip), 820.0, 820.2, 820.8 (nonpathologic hip). We further examined the proportion of cases with a diagnosis of a malignancy proximate to the fracture.
We identified 44,120 individuals with a vertebral fracture and 60,354 with a hip fracture. Approximately 48% of vertebral fractures and 3% of hip fractures were coded as pathologic. For only approximately 25% of persons with a "pathologic" vertebral fracture ICD-9 code, but 66% of persons with a "pathologic" hip fracture, there was evidence of a possible cancer diagnosis.
Among US Medicare beneficiaries, one fourth of pathologic vertebral fracture and two thirds of pathologic hip fracture cases had evidence for a malignancy. Particularly for vertebral fractures, excluding persons with pathologic fractures in epidemiologic analyses that utilize administrative claims data substantially underestimates the burden of fractures due to osteoporosis.
在骨质疏松症的流行病学研究中,病理性骨折通常被排除在外。我们使用医疗保险管理数据确定了椎体和髋部骨折患者。其中,48%(椎体)和 3%(髋部)的骨折被编码为病理性骨折。仅有 25%和 66%的病理性骨折患者有恶性肿瘤的证据。
分析使用管理数据的骨质疏松症相关骨折时,由于担心这些骨折是由癌症引起的,通常会排除病理性骨折(ICD-9 733.1x)。我们评估了椎体和髋部的“病理性”骨折,以评估其对骨折发生率的贡献,并评估恶性肿瘤的证据。
我们研究了美国 Medicare 年龄≥65 岁的受益人的新骨折,这些骨折是通过 ICD-9 诊断代码 733.13(病理性椎体)、805.0、805.2、805.4、805.8(非病理性椎体)和 733.14(病理性髋部)、820.0、820.2、820.8(非病理性髋部)来识别。我们进一步检查了与骨折相邻的恶性肿瘤诊断比例。
我们确定了 44120 例椎体骨折患者和 60354 例髋部骨折患者。约 48%的椎体骨折和 3%的髋部骨折被编码为病理性骨折。仅有约 25%的椎体骨折患者(ICD-9 代码为“病理性”)和 66%的髋部骨折患者(ICD-9 代码为“病理性”)有恶性肿瘤诊断的可能。
在美国 Medicare 受益人群中,四分之一的病理性椎体骨折和三分之二的病理性髋部骨折患者有恶性肿瘤的证据。特别是对于椎体骨折,在利用管理索赔数据进行的流行病学分析中排除病理性骨折患者,大大低估了骨质疏松症引起的骨折负担。